Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma

Annals of Surgery

Volumn 252, Issue 3, 2010, Pages 460-465

  McMasters, Kelly M ^a   Edwards, Michael J ^b   Ross, Merrick I ^c   Reintgen, Douglas S ^d   Martin, Robert C G ^a   Urist, Marshall M ^e   Noyes, R Dirk ^f   Sussman, Jeffrey J ^b   Stromberg, Arnold J ^g   Scoggins, Charles R ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Lakeland Regional Cancer Center   (United States)

^e Kentucky   (United States)

^f LDS HOSPITAL   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; INTERFERON; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGED; CHEMICALLY INDUCED; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MIDDLE AGED; NORTH AMERICA; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; SKIN ULCER; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERONS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NORTH AMERICA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SKIN ULCER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77956196304     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181f20bb1     Document Type: Article

References (27)

1. Allen AC, Spitz S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1-45.
2. Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742.
3. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012-3017.
4. Balch CM, Soong SJ, Milton G, et al. A comparison of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg. 1982;196:677-684.
5. Eigentler TK, Buettner PG, Leiter U, et al. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol. 2004;22:4376-4383.
6. Masback A, Olsson H, Westerdahl J, et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Mel Res. 2001;11:435-445.
7. Grande Sarpa H, Reinke K, Shaikh L, et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol. 2006;30: 1396-1400.
8. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
10. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
11. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.
12. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.
13. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19: 2370-2380.
14. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241-252.
15. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:493-501.
16. Janku F, Kurzrock R. Adjuvant interferon in high-risk melanoma: end of the era? J Clin Oncol. 2010;28:e15-e16.
17. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189-1196.
18. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegy-lated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-126.
19. McMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol. 2001;8(suppl 9):41S-43S.
20. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006;24:2849-2857.
21. McMasters KM, Ross MI, Reintgen DS, et al. Final results of the Sunbelt Melanoma Trial [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 9003 available at: http://meeting.ascopubs.org/cgi/content/abstract/26/15-suppl/9003.
22. Mascaro JM, Castro J, Castel T, et al. Why do melanomas ulcerate? J Cut Path. 1984;11:269-273.
23. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
24. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol. 2002; 20:1826-1831.
25. Kashani-Sabet M, Shaikh L, Miller JR III, et al. NF-kB in the vascular progression of melanoma. J. Clin Oncol. 2004;22:617-623.
26. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery. 2001;130:151-156.
27. Eggermont AM, Suciu S, Ruka W, et al. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [abstract]. J Clin Oncol. 2008;26(suppl). Abstract 9004 available at: http://meeting.ascopubs.org/cgi/content/abstract/26/15- suppl/9004.